NCT07784114Completed
Incremental Value of Traditional Chinese Medicine Features in Two-Stage Pre-Endoscopic Prediction
Incremental Value of a Traditional Chinese Medicine-Integrated Versus Western-Only Strategy for Two-Stage Pre-Endoscopic Prediction of Colorectal Inflammatory Conditions: A Multicenter Diagnostic Model Development and External Validation Study
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
This observational study evaluates whether adding Traditional Chinese Medicine (TCM)-related clinical features improves the performance of machine-learning models that estimate disease risk before colonoscopy. We compare two modeling strategies that use the same sequential (two-stage) framework: Western-only models, based on demographic, clinical, and laboratory information commonly used in Western medicine. TCM-integrated models, which use the same types of Western information plus structured TCM features. Stage 1 aims to distinguish people more likely to have functional bowel problems from those more likely to have inflammatory or neoplastic colorectal disease. Stage 2 focuses on people in the higher-risk pathway and aims to distinguish ulcerative colitis from other inflammatory or neoplastic conditions. Models are developed in one dataset and tested in independent external data from other centers. We assess discrimination (including AUC), clinical usefulness with decision-curve analysis, and which TCM features contribute most in the integrated models. This study does not assign treatments. It analyzes existing clinical information to support future pre-endoscopic triage research. Results will not replace colonoscopy or clinician judgment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1500 (actual)
- First submitted
- 15 Aug 2026
- Start date
- 1 Jan 2015
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Beijing University of Chinese Medicine
- NCT number
- NCT07784114
What you commit to
- Study type: Observational
- Participants enrolled: 1500
- From 1 Jan 2015 to the primary completion date, 1 Jun 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age younger than 18 years Missing or unverifiable final diagnostic label required for Stage 1 and/or Stage 2 Missing key predictors required by the Western-only and/or TCM-integrated modeling pipelines (per protocol variable lists) Diagnosis outside the predefined Stage 1 / Stage 2 label sets and not mappable under protocol rules Duplicate or overlapping records for the same patient encounter after de-duplication Records excluded by pre-specified data-quality or center-specific protocol rules (e.g., incomplete critical clinical documentation)
Who the study is looking for
- Adults aged 18 years or older Patients evaluated in participating centers with clinical records suitable for pre-endoscopic risk assessment related to colorectal inflammatory or functional bowel conditions Underwent colonoscopy (or had a colonoscopy-confirmed final diagnosis) allowing assignment to the study diagnostic labels used in the two-stage framework Stage 1-eligible diagnoses classifiable as either a functional-predominant pathway (e.g., irritable bowel syndrome / related functional presentations as defined in the protocol) or an inflammatory-neoplastic pathway (ulcerative colitis, Crohn disease, indeterminate colitis, or colorectal neoplasia as defined in the protocol) For Stage 2 analyses: patients within the inflammatory-neoplastic pathway classifiable as ulcerative colitis versus other inflammatory or neoplastic conditions (Crohn disease, indeterminate colitis, or colorectal neoplasia) Availability of required Western clinical and laboratory predictors for model development or validation For TCM-integrated analyses: availability of protocol-defined structured Traditional Chinese Medicine (TCM) features Ability to assign the record to the development cohort or an independent external-validation cohort according to the protocol center rules
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.